Literature DB >> 2833331

Selective generation of erythroid burst-promoting activity by recombinant interleukin 2-stimulated human T lymphocytes and natural killer cells.

S Skettino1, J Phillips, L Lanier, A Nagler, P Greenberg.   

Abstract

Because T lymphocytes and natural killer (NK) cells produce a variety of growth factors and interleukin 2 (IL2) modulates the activity of both, we assessed the ability of IL2 to stimulate human T cells and NK cells to produce hematopoietic growth factors detectable in clonogenic marrow culture. Human recombinant interleukin 2 (rIL2) added directly to cultures of human bone marrow that had been depleted of monocytes or depleted of both monocytes and T cells caused no significant alteration of myeloid (CFU-GM) or erythroid colony formation. Conditioned media harvested from rIL2-stimulated (greater than 100 U/mL) peripheral blood mononuclear cells, T cells, Leu-2 cells, and Leu-3 cells all had erythroid burst-promoting activity (BPA) but lacked myeloid colony-stimulating factor (GM-CSF) or CFU-GM-inhibitory activity. These T cells were IL2 receptor-negative, and the addition of anti-IL2 receptor monoclonal antibody (anti-Tac) to T cell cultures did not abrogate this IL2-stimulated BPA production. In addition, Percoll gradient-enriched, large granular lymphocytes (LGL) were separated by fluorescence-activated cell sorting into Leu-11+ (NK) cells and Leu-11- (low-density Leu-4+ T) cell fractions. rIL2 stimulated LGL, Leu-11+ and Leu-11- cells to produce BPA but not detectable GM-CSF or CFU-GM-inhibitory activity. Leu-11+ (NK) cells were Tac-negative from days 0 through 14 of culture. We conclude that rIL2 at high concentrations stimulated T cells, Leu-2 and Leu-3 cell subsets, LGL, and NK cells to produce BPA but not GM-CSF and that this stimulation may be mediated by an IL2 receptor distinct from Tac or by an epitope of the IL2 receptor not recognized by the anti-Tac antibody.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833331

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Effects of interleukin-2 and interleukin-2-activated cells on in vitro myelopoiesis.

Authors:  M Clerigue; P Pisa; L Tsai; M Hanson
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

2.  Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.

Authors:  L J Levitt; A Nagler; F Lee; J Abrams; M Shatsky; D Thompson
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Authors:  J W Gratama; R J Bruin; C H Lamers; R Oosterom; E Braakman; G Stoter; R L Bolhuis
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

4.  Long-term human hematopoiesis in the SCID-hu mouse.

Authors:  R Namikawa; K N Weilbaecher; H Kaneshima; E J Yee; J M McCune
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

5.  Production of hematopoietic colony-stimulating factors by human natural killer cells.

Authors:  M C Cuturi; I Anegón; F Sherman; R Loudon; S C Clark; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.